JAM
ADMS

JW Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

JW Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-30,140
Closed -$495K – 45
2016
Q3 		$495K Hold
30,140
– – 0.34% 26
2016
Q2 		$456K Hold
30,140
– – 0.36% 28
2016
Q1 		$436K Hold
30,140
– – 0.28% 27
2015
Q4 		$854K Hold
30,140
– – 0.32% 26
2015
Q3 		$505K Buy
+30,140
New +$686K 0.18% 38

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

JW Asset Management's ADMS Position: Q4 2016 in Review

JW Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q4 2016, closing a stake of 30,140 shares — an estimated $495K sold.

JW Asset Management first reported a position in ADMS in Q3 2015 and held it in 5 quarters. The position peaked at $854K in Q4 2015. 78 funds tracked by Wall St. Rank hold ADMS as of Q4 2016.

  • JW Asset Management reported no remaining Adamas Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • JW Asset Management sold 30,140 Adamas Pharmaceuticals shares in Q4 2016, an estimated $495K.
  • JW Asset Management first reported a position in Adamas Pharmaceuticals in Q3 2015 and held it in 5 quarters.
  • JW Asset Management's Adamas Pharmaceuticals position peaked at $854K in Q4 2015.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2016.

Based on JW Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.